Lutris Pharma, a Tel Aviv, Israel-based clinical stage biopharmaceutical company, raised $30M in funding.
The round was led by Columbus Venture Partners and Pontifax Venture Capital, with participation from an existing investor, with Peregrine Ventures and aMoon Fund.
The company intends to use the funds to advance the development of LUT014, an innovative topically applied gel aimed at reducing EGFRi-induced rashes, a common adverse side effect of these cancer-fighting therapies.
Led by CEO Noa Shelach, Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Its lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary small molecule currently completed a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and has successfully completed a phase 1/2 study for the treatment of radiation-induced dermatitis in breast cancer patients.
FinSMEs
28/01/2025